We tested 11 hammerhead ribozymes for their ability to bind and cleave RNA transcripts of the cytostatic drug resistance-associated glypican-3-encoding gene (GPC3, MXR7, OCI-5). To select the optimum target sequence, the activity of each hammerhead ribozyme was tested in a short in vitro assay using truncated RNA substrates without time-consuming cloning procedures. Glypican-3-derived RNA was cleaved effectively by 3 of 11 hammerhead ribozymes. One of these, the hammerhead ribozyme Rz967, recognized the GUC sequence at nucleotides ϩ965 to ϩ967 of the open reading frame of the glypican-3-encoding mRNA. Rz967 cleaved in vitro-transcribed fragments derived from glypican-3 mRNA (nucleotides ϩ803 to ϩ1036) most efficiently. Cleavage efficiency was confirmed by a rapid in vitro assay using full-length total tumor cell RNA. We were able to demonstrate that this new in vitro assay is suitable for the selection of hammerhead ribozymes that have the capability to cleave glypican-3-encoding mRNA in human tumors.
C hanges in the transmembrane heparan sulfate proteoglycan glypican-3 cause Simpson-Golabi-Behmel syndrome (SGBS). 1 SGBS is characterized by pre-and postnatal overgrowth, resulting in visceral and skeletal anomalies. Patients are also at high risk for the development of embryonic tumors, including Wilms' tumors and neuroblastomas, during early childhood. 2 Recently, it was shown that the expression of glypican-3-encoding mRNA contributes to tumor progression in hepatocellular carcinoma (HCC), and that glypican-3 mRNA expression might be a more sensitive early tumor marker for HCC than ␣-fetoprotein. 3 Considerable overexpression of the glypican-3-encoding gene GPC3, also designated as OCI-5 4 or MXR7 5 , was observed in the cytostatic drug-resistant gastric carcinoma cell line EPG85-257RNOV. 5 This cell line, which was selected against mitoxantrone in vitro, exhibits an atypical multidrug resistance (MDR) phenotype accompanied by vesicular compartmentalization of the drug 6 and decreased DNA-topoisomerase II␣ content. 7 High expression levels of the glypican-3-encoding gene were also observed in colorectal tumors in vivo. 8 Hammerhead ribozymes initially derived from plant viroids 9 can be designed to cleave a target RNA at a defined position in trans, provided the RNA contains a NUX motif, in which "N" is any nucleotide (nt) and "X" is A, C, or U. 10, 11 The ability of hammerhead ribozymes to inactivate multiple copies of target RNA may solve the problems of stoichiometry that are inherent in the antisense approach. Therefore, the application of ribozymes may result in greater inhibition of gene expression.
In the present study, a cell-free assay was chosen to select effective hammerhead ribozymes against glypican-3-specific mRNA. Cleavage activity was confirmed with a rapid in vitro assay using total RNA from gastric carcinoma cells. Of the 11 hammerhead ribozymes examined, one was able to specifically destroy the glypican-3-encoding mRNA molecule at a high efficiency. Therefore, this hammerhead ribozyme (Rz967) may be helpful for new therapeutic approaches aimed at modulating the atypical MDR of tumor cells. In addition, Rz967 may support additional investigations of the involvement of glypican-3 in cancer.
MATERIALS AND METHODS

Truncated target transcripts
Four different truncated glypican-3-encoding DNA molecules were generated by polymerase chain reaction (PCR) using the corresponding glypican-3 cDNA clone pMXR7 5 as a template. In each case, the forward sense primer was 5Ј-linked with a T7 RNA-polymerase promoter sequence. The oligonucleotide primers used for the amplification of substrate 1-encoding sequences were SUB1-fw (nt ϩ20 to ϩ38), 5Ј-TAATAC-GACTCACTATAGCCGCGTGCTTGGTGGTGGC-3Ј (T7 promoter-encoding sequence underlined) and SUB1-rev (nt ϩ255 to ϩ277), 5Ј-GCAGCTGTTCCATGTTCAATCGT-3Ј, yielding an expected product of 258 base pairs (bp); the primers used for the amplification of substrate 2-encoding sequences were SUB2-fw (nt ϩ348 to ϩ367), 5Ј-TAATAC-GACTCACTATAGAATTGTTGTTCGCCATGCCA-3Ј (T7-promoter encoding sequence underlined) and SUB2-rev (nt ϩ542 to ϩ563), 5Ј-GGCAGGCCTGGGTTCATTAGCT-3Ј, yielding an expected product of 216 bp; the primers used for the amplification of substrate 3-encoding sequences were SUB3-fw (nt ϩ803 to ϩ824), 5Ј-TAATACGACTCACTAT-AGTGATGATGGTTAAACCCTGTGG-3Ј (T7-promoter encoding sequence underlined) and SUB3-rev (nt ϩ1013 to ϩ1036), 5Ј-CAATAGTGGTGGTCAGCTTTCCT-3Ј, yielding an expected product of 234 bp; finally, the primers used for the amplification of substrate 4-encoding sequences were SUB4-fw (nt ϩ1155 to 1176), 5Ј-TAATACGACTCACTATAGCAGC-CGAAGAAGGGAACTAATT-3Ј (T7-promoter encoding sequence underlined) and SUB4-rev (nt ϩ1466 to ϩ1487), 5Ј-CCACTTTCAAACCCTTCCTCAT-3Ј, yielding an expected product of 333 bp. To generate RNA-encoding DNA templates, the reaction mixture contained 100 ng of pMXR7, 10 M of each oligonucleotide primer, 0.5 M of deoxynucleoside triphosphate, 50 mM KCl, 10 mM tris(hydroxymethyl) aminomethane (Tris)-HCl (pH 8.3), 1 mM MgCl 2 , 0.01% gelatin, and 1 U of AmpliTaq Gold (Perkin Elmer, Norwalk, Conn) in a final volume of 50 L. Cycling conditions were 12 minutes at 93°C followed by 35 cycles consisting of 60 seconds at 93°C, 90 seconds at 55°C, and 90 seconds at 72°C. The last cycle contained a 5-minute extension step at 72°C. Subsequently, the PCR products were purified with Sephadex G-50 columns. The four different glypican-3-specific RNA fragments (substrates 1 through 4) were obtained by performing in vitro transcription. In each case, the sequences and nt positions were derived from a human pMXR7 cDNA sequence (EMBL accession number Z37987). 5 The nt position ϩ1 is assigned to the A residue of the ATG translation start codon.
Construction and synthesis of hammerhead ribozymes
Following a computer-based secondary structure analysis (DNASIS, Hitachi, Yokohama, Japan) of the glypican-3-encoding mRNA, potential hammerhead ribozyme cleavage sites were selected at nt 106 (site of substrate 1), nt 458 (site of substrate 2), nt 501 (site of substrate 2), nt 843 (site of substrate 3), nt 905 (site of substrate 3), nt 967 (site of substrate 3), nt 1002 (site of substrate 3), nt 1190 (site of substrate 4), nt 1377 (site of substrate 4), nt 1381 (site of substrate 4), and nt 1430 (site of substrate 4). These target sequences were not blocked by any secondary structures. In addition, the predicted size of the cleavage products of the truncated RNA transcripts should allow for easy identification of each fragment. The hammerhead ribozymes were named Rz106, Rz458, Rz501, Rz843, Rz905, Rz967, Rz1002, Rz1190, Rz1377, Rz1381, and Rz1430 according to the nt immediately downstream from the predicted cleavage site. As an example, Figure 1 shows the schematic structure of ribozyme Rz967 in relation to its target site. For each hammerhead ribozyme, an encoding sense single-stranded DNA (ssDNA) (5Ј-linked with a T7 RNApolymerase promoter sequence) (sequences are shown in Table 1 ) as well as the homologous antisense ssDNA were synthesized on an oligonucleotide synthesizer. Using these template molecules, the hammerhead ribozymes were obtained by in vitro transcription.
In vitro transcription and purification of RNA molecules
In vitro transcription was performed in a reaction mixture containing 500 ng of PCR-generated template DNA (substrates) or synthesizer-generated ribozyme template, 0.5 M of nucleoside triphosphate, 10 Ci of [␣-
32 P]uridine triphosphate, 1 U of ribonuclease inhibitor, and 20 U of T7 RNApolymerase in a total volume of 50 L with 40 mM Tris-HCl (pH 8.0), 1 mM MgCl 2 , 50 mM dithiothreitol, 0.5 mg/mL bovine serum albumin, and 0.1% Triton X-100. The reaction was performed for 2 hours at 37°C. After precipitation, substrates or ribozymes, respectively, of all transcription mixtures were size-fractionated on an 8% polyacrylamide gel containing 7 M urea, identified by autoradiography, and eluated with 500 mM Tris-HCl (pH 8.0), 0.1 mM ethylenediaminetetraacetic TAA TAC GAC TCA CTA TAG TTG GTC TGA TGA GTC CGT GAG GAC GAA ACA GGT GGC G  Rz458  TAA TAC GAC TCA CTA TAG AGA GAC TGA TGA GTC CGT GAG GAC GAA ACA CAT CTG T  Rz501  TAA TAC GAC TCA CTA TAG TCA TTC TGA TGA GTC CGT GAG GAC GAA ACC ATG TCA T  Rz843  TAA TAC GAC TCA CTA TAG TGC ATC TGA TGA GTC CGT GAG GAC GAA ACC ACA TTG C  Rz905  TAA TAC GAC TCA CTA TAG CAA GGC TGA TGA GTC CGT GAG GAC GAA ACA GAA TGT A  Rz967  TAA TAC GAC TCA CTA TAG AAA GAC TGA TGA GTC CGT GAG GAC GAA ACC AAG CAG T  Rz1002  TAA TAC GAC TCA CTA TAG TTC TGC TGA TGA GTC CGT GAG GAC GAA ACA TAC TGG A  Rz1190  TAA TAC GAC TCA CTA TAG TGA AAC TGA TGA GTC CGT GAG GAC GAA ACT TCA ACT T  Rz1377  TAA TAC GAC TCA CTA TAG TGA CTC TGA TGA GTC CGT GAG GAC GAA ACC ACT GGC T  Rz1381  TAA TAC GAC TCA CTA TAG AAT TTC TGA TGA GTC CGT GAG GAC GAA ACT GAC CAC T  Rz1430  TAA TAC GAC TCA CTA TAG GCA TAC TGA TGA GTC CGT GAG GAC GAA ACA TGG TTC T acid (EDTA), and 0.1% sodium dodecyl sulfate (SDS). After ethanol precipitation, the transcripts were quantified by measuring the radioactivity in a scintillation counter, dissolved in ribonuclease-free water, and stored at Ϫ80°C.
Kinetic experiments using truncated RNA transcripts and ribozyme excess
Screening of candidate ribozymes. Cleavage reactions were performed in a final volume of 10 L containing 40 mM Tris-HCl (pH 7.5) and 12 mM MgCl 2 at 37°C. The ability of the hammerhead ribozymes to cleave the target RNA was assayed using 80 nM of hammerhead ribozyme and 40 nM of the target molecule, resulting in a 2-fold molar excess of hammerhead ribozyme molecules. Samples were removed after various time intervals and quenched by adding an equal volume of 8 M urea, 10 mM EDTA (pH 8.0), 0.3% xylene cyanol, and 0.3% bromophenol blue. Each sample was size-fractionated on an 8% polyacrylamide gel containing 7 M urea. Substrates and cleavage products were identified by autoradiography, scanned, and counted to determine the extent of cleavage. Afterward, these data were plotted for each reaction. As a result of this procedure, one of the 11 ribozymes (Rz967) tested was detected rapidly as the ribozyme that was able to cleave most efficiently (data not shown). Accordingly, all subsequent in vitro cleavage assays were performed with Rz967 and substrate 3 RNA as a target.
Turnover kinetics. The initial velocity (v ini ) of the reaction was estimated by measuring the amount of 32 P-labeled substrate and formed cleavage products after 0, 1, 2, 3, 5, 10, 20, 30, 60, and 120 minutes using 40 nM of substrate and 200 nM of hammerhead ribozyme. The reaction was started by adding the 234-mer substrate 3 to the reaction mix containing Rz967, 40 mM Tris-HCl (pH 7.5), and 12 mM MgCl 2 at 37°C. All experiments were performed at least in triplicate. Substrate/ product ratios were estimated following polyacrylamide gel electrophoresis of the reaction mixtures and autoradiography by densitometric measurement. The value for v ini was calculated from the ascent of the graph in the product-time diagram.
The reaction parameter k cat /k m was determined using 40 nM of substrate and ribozyme equaling 20, 40, 80, 120, 200, 300, 400, and 500 nM; the reaction lasted for 11 minutes. The reaction was started by adding the 234-mer substrate 3 to the reaction mix containing Rz967, 40 mM Tris-HCl (pH 7.5), and 12 mM MgCl 2 at 37°C. All experiments were performed at least in triplicate and analyzed as described above. The reaction parameter k cat /k m was determined using the equation given by Heidenreich and Eckstein: 
AGA ACC AUG UC 2 U AUG C Ϫ *Sequences and nt positions are derived from a human pMXR7 cDNA sequence (EMBL accession number Z37987). 5 The nt position ϩ1 is assigned to the A residue of the ATG translation start codon. The number of the hammerhead ribozyme denotes the last nt within the NUX motif (underlined). The cleavage positions are indicated by an arrow.
†Cleavage activity was determined as described in Materials and Methods. Using a 2-fold molar excess of hammerhead ribozyme, the cleavage reaction was performed at 37°C and quenched after 60 minutes. Substrates and cleavage products were identified by autoradiography, scanned, and counted to determine the extent of cleavage. The in vitro cleavage activities using truncated RNA targets are indicated: Ϫ, no activity (no formation of cleavage products); ϩ, weak activity (formation of Ͻ20% cleavage products); ϩϩ, moderate activity (formation of 21-30% cleavage products); and ϩϩϩ, high activity (formation of Ͼ31% cleavage products).
where the percentage of uncleaved substrate (S u ) per reaction time (t) was plotted against the ribozyme concentration ([ribozyme]). P t is the amount of cleavage products at time (t). This calculation is based on the accepted supposition that the cleavage of the first 30% of the substrate follows a linear curve and that the whole amount of given substrate is cleavable. Under these circumstances, the k cat /k m value corresponds to the ascent of the linear beginning of the graph.
To compare the value for k cat /k m with those calculated by a different method, the k cat /k m value was also determined by the equation of Hendry et al:
P t and t are the same as described above, P ϱ is the amount of cleavage products at that point of t ϭ ϱ when the reaction rate was constant, and P ⌬ is the difference between the percentage of cleavage products at t ϭ ϱ and t ϭ 0. This calculation is based on the supposition that the cleavage of the first 30% of the substrate follows a linear curve as well, but, in contrast to the upper calculation, regards only that amount of cleavable substrate that is actually cleaved after a considerable amount of time (here: 2 hours; described as t ϭ ϱ). For these k cat /k m values corresponding to the ascent of the linear beginning of the graphs, it is obvious that the results gained by these two procedures must differ.
In vitro cleavage assay containing total cellular RNA
The highly cytostatic, drug-sensitive gastric carcinoma cell line EPG85-257P and the atypical multidrug-resistant subline EPG85-257RNOV 6 were used. The atypical multidrug-resistant cell variant EPG85-257RNOV exhibits a distinct overexpression of the glypican-3-encoding mRNA. 5 The cell lines were grown as described previously. 6 The drug-resistant variant was also cultivated in the presence of 0.2 g/mL mitoxantrone. Total cellular RNA from gastric carcinoma cells was extracted by a modified one-step guanidinium isothiocyanatephenol-chloroform extraction procedure.
14 The yield and purity of the RNA were checked by spectrophotometric determination at 260 and 280 nm and by agarose gel electrophoresis. Subsequently, the total RNA cleavage reaction was performed in a final volume of 50 L using 20 g of total RNA and 50 mM of Rz967 in 40 mM Tris-HCl (pH 7.5) and 10 mM MgCl 2 at 37°C for 0, 1, 3, 4, 5, and 7 hours. Afterward, the RNA was precipitated, denatured in 50% formamide containing 2.2 M formaldehyde at 65°C, and fractionated by electrophoresis on a 1% agarose gel containing 2.2 M formaldehyde. The RNA samples were transferred by capillary forces to a Hybond-N membrane in 20ϫ SSC buffer and were immobilized for 2 hours at 80°C. The membrane was prehybridized for 1 hour at 68°C in 6ϫ standard saline phosphate/EDTA, 10% dextran sulfate, 7% SDS, and 0.5% Blotto (50 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 5% nonfat dry milk). Hybridization with glypican-3 encoding a 2.3-kilobase BamHI cDNA fragment from pMXR7 5 was performed overnight in the same buffer at 68°C with the 32 P-labeled cDNA probe prepared using a Multiprime DNA Labeling Kit (Amersham, Aylesbury, U.K.). Finally, the membrane was washed under high-stringency conditions (0.1ϫ SSC and 1% SDS at 65°C), and an autoradiogram was produced. Densitometry measurement of the autoradiogram enabled the calculation of the product/sub- strate ratio in such a way that the percentage of cleavage products (P t ) could be graphed against the reaction time. This way, the time course of the reaction as well as the extent of the ability of the ribozyme to cleave its substrate during a given period could be followed easily.
RESULTS
In vitro synthesis of substrate and hammerhead ribozyme RNA The truncated substrate-specific oligonucleotide primers, which were 5Ј-linked with T7 promoter sequences, were applied successfully for PCR-based DNA template synthesis. These templates, which encoded truncated substrate RNA molecules, were suitable for direct in vitro transcription without any cloning procedures. The same was true for the 5Ј-linked T7 promoter sequence containing synthetic DNA molecules, which encoded hammerhead ribozymes.
Selection of a high-activity hammerhead ribozyme against glypican-3-encoding mRNA We designed 11 different hammerhead ribozymes with asymmetric 10-nt 5Ј-antisense arms and 5-nt 3Ј-antisense arms according to the method of Haseloff and Gerlach. 9 The catalytic RNA molecules were tested in a cell-free assay for their ability to cleave in vitro-transcribed truncated fragments of the glypican-3-encoding mRNA. The substrate fragment size ranged from 216 to 333 nt. Hammerhead ribozymes targeting the GUC motifs 843, 967, and 1002 were able to cleave truncated fragments of glypican-3-encoding mRNA when a molar excess of hammerhead ribozyme RNA was present in the cleavage reaction (Table 2 ). Hammerhead ribozyme Rz967 (Fig  1) also cleaved the truncated glypican-3-encoding mRNA fragment very efficiently when a molar excess of substrate (4:1) was present in the cleavage reaction (data not shown). The remaining eight hammerhead ribozymes tested were not active. The capacity of hammerhead ribozymes Rz843, Rz967, and Rz1003 to cleave the target sequences was dependent upon the concentration of Mg 2ϩ , temperature, time, and substrate/ribozyme ratio (data not shown). Rz967 was apparently far more active than Rz843 and Rz1002. Therefore, it was selected for further examinations. The amount of cleavage products was measured when the cleavage rate became constant. This value (P ϱ ) was typically in the region of 0.45 (i.e., ϳ45% of the substrate was cleaved at the end of the reaction). The v ini of the ribozyme catalyzed reaction was calculated as follows: v ini ϭ 0.155 Ϯ 0.034 fmol s Ϫ1 (Figs 2 and 3) . (Fig 4) according to the equation given by Heidenreich and Eckstein. 12 The value of the kinetic parameter k cat /k m for Rz967 is presented (Table 3) in comparison with that of other hammerhead ribozymes.
Effect of Rz967 on full-length glypican-3-encoding mRNA in the presence of total cellular RNA Because Rz967 was found to be effective against truncated glypican-3-encoding RNA transcripts, this hammerhead ribozyme was used to cleave the original 2.6-kilobase, full-length glypican-3-encoding mRNA in the presence of total cellular RNA. The latter was isolated from drug-sensitive or cytostatic drug-resistant gastric carcinoma cells, respectively. Rz967 was suitable for the specific destruction of the glypican-3-encoding mRNA from parental as well as drug-resistant cells at 37°C in vitro. Only 50 mM of Rz967 was required to decrease the initial amount of glypican-3-encoding mRNA after 4 hours to 50% at 37°C from total cellular RNA of the cytostatic drug-resistant gastric carcinoma cell line EPG85-257RNOV. The glypican-3-encoding mRNA of parental cells was decreased to one-third of the initial amount by 4 hours and to 20% by 7 hours. Cleavage of the glypican-3-encoding mRNA synthesized by the drug-resistant variant EPG85-257RNOV required more time; however, 50% of the mRNA was decreased after 7 hours (Fig 7) .
DISCUSSION
Hammerhead ribozymes can be designed to target virtually any RNA provided that a NUX motif is present.
Therefore, these ribozymes have a substantial potential to specifically modulate the expression of functionally important cancer-associated genes. For example, hammerhead ribozymes have been applied successfully to cleave oncogenes such as c-fos, 15 H-ras, 16 or c-myc 17 . Hammerhead ribozymes against the classical MDRrelated factor P-glycoprotein have been constructed successfully as well. 18, 19 Hammerhead ribozymes against other important cytostatic drug resistance-associated proteins such as the ABC-transporters (adenosine Figure 5 . Experimental determination of the reaction parameter k cat /k m according to Hendry et al. 13 The negative natural logarithm of the amount of formed cleavage products (P t ) was plotted against the concentration of the ribozyme. The value of k cat /k m ϭ 10625 Ϯ 970 M Ϫ1 s Ϫ1 corresponds to the ascent of the linear beginning of the curve (small inserted figure). triphosphate binding cassette-transporters), MRP (multidrug resistance associated protein) and cMOAT canalicular multispecific anion transporter) or against the major vault protein designated as LRP (lung resistanceassociated protein) have not been described yet. Therefore, a hammerhead ribozyme against glypican-3, which is considerably overexpressed in an atypical multidrugresistant gastric carcinoma cell line, might be a new candidate for modulating cytostatic drug resistance. Problems designing hammerhead ribozymes arise because various sites in a particular mRNA may not be accessible for base pairing and because cleavable sites often are unpredictable. Therefore, optimal target sites for hammerhead ribozymes have to be selected empirically. In addition, hammerhead ribozymes that are found to be catalytically active to cleave truncated RNA substrates often show poor potency when applied to total full-length RNA. Hence, active hammerhead ribozymes against glypican-3-encoding mRNA were selected first in an uncomplicated assay using truncated RNA substrates. The assay was aimed both at finding target sites within the glypican-3-encoding mRNA that are accessible for base pairing and at selecting hammerhead ribozymes with the highest catalytic potency. In the second step, one hammerhead ribozyme was applied to an assay, including total full-length RNA, to verify its potency to cleave the glypican-3-encoding mRNA.
In comparison with short oligonucleotide substrates, drastic decreases (100-to 1000-fold) in cleavage efficiencies have been reported for ribozymes directed against substrates in the size range between 60 and 954 nt. 12, 20, 21 Large RNA molecules form complex secondary and tertiary structures that can interfere with the recognition and cleavage by hammerhead ribozymes. Very likely, the rate-limiting step is the finding of the target sequence. In addition, tertiary interactions can slow down product release and interfere with turnover. For this reason, only a few hammerhead ribozymes constructed exhibit a high catalytic activity with long substrates. 22, 23 The catalytic parameters of Rz967 show values that are comparable with some of these hammerhead ribozymes (Table 3) . Accordingly, it can be concluded that the glypican-3-encoding target is very accessible to Rz967. 
259
ND 47500 § *Calculated by the method of Hendry et al. 13 †Calculated by the method of Heidenreich and Eckstein. 12 ‡Reactions were performed at 37°C. §Reactions were performed at 42°C. Figure 7 . Cleavage of glypican-3-encoding mRNA in the presence of total full-length cellular RNA of the non-resistant parental cell line EPG85-257P (F) and the cytostatic drug-resistant cell line EPG85-257RNOV (OE). The formed cleavage products ( P t ) are plotted as a function of the time (t). The relative portion of the glypican-3-encoding mRNA is smaller in the nonresistant cell line; therefore, more cleavage products result from these cells.
Furthermore, it could be demonstrated that Rz967 is able to detect and cleave the glypican-3-encoding mRNA in a mixture containing total cellular RNA. Using full-length total RNA from the cytostatic drugresistant gastric carcinoma cell line EPG85-257RNOV, the cleavage reaction was less effective when compared with the cleavage efficiency using total cellular RNA from the nonresistant variant EPG85-257P. This effect might originate from the fact that the nonresistant tumor cells synthesized much less glypican-3-encoding mRNA. For this reason, the same amount of hammerhead ribozyme is able to destroy much more specific mRNA molecules isolated from nonresistant cancer cells.
Hammerhead ribozymes have been proposed as antiviral agents, as tools to help study gene expressions, and as tools to modulate the malignant phenotype of tumor cells. Our experiments show that the antiglypican-3 hammerhead ribozyme Rz967 can be targeted to cleave the glypican-3-encoding mRNA among the total fulllength tumor RNA, and may represent a potential help in an additional strategy of cancer research. The hammerhead ribozyme Rz967 may be useful in studying the involvement of glypican-3 with regard to the development of embryonic tumors, such as Wilms' tumors and neuroblastomas, and in the investigation of the role of glypican-3 in HCC. Moreover, Rz967 may serve to explore the role of glypican-3 in SGBS. Another important application of this hammerhead ribozyme concerns additional investigations of the putative role of glypican-3 in cytostatic drug resistance. The reported data were obtained with cell-free systems, and the relevance in tumor cells remains to be demonstrated. For this reason, we are planning to design a recombinant adenovirus-based delivery system expressing the hammerhead ribozyme Rz967 in functioning tumor cells.
